163 related articles for article (PubMed ID: 17713163)
1. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C.
Males S; Gad RR; Esmat G; Abobakr H; Anwar M; Rekacewicz C; El Hoseiny M; Zalata K; Abdel-Hamid M; Bedossa P; Pol S; Mohamed MK; Fontanet A
Antivir Ther; 2007; 12(5):797-803. PubMed ID: 17713163
[TBL] [Abstract][Full Text] [Related]
2. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
3. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
4. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C.
Gad RR; Males S; El Makhzangy H; Shouman S; Hasan A; Attala M; El Hoseiny M; Zalata K; Abdel-Hamid M; Fontanet A; Mohamed MK; Esmat G
Liver Int; 2008 Sep; 28(8):1112-9. PubMed ID: 18397226
[TBL] [Abstract][Full Text] [Related]
5. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
[TBL] [Abstract][Full Text] [Related]
6. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
Takayama K; Furusyo N; Ogawa E; Ikezaki H; Shimizu M; Murata M; Hayashi J
World J Gastroenterol; 2015 Apr; 21(15):4696-706. PubMed ID: 25914481
[TBL] [Abstract][Full Text] [Related]
7. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C.
Diago M; Castellano G; García-Samaniego J; Pérez C; Fernández I; Romero M; Iacono OL; García-Monzón C
Gut; 2006 Mar; 55(3):374-9. PubMed ID: 16150856
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
9. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
[TBL] [Abstract][Full Text] [Related]
10. Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
Lange CM; von Wagner M; Bojunga J; Berg T; Farnik H; Hassler A; Sarrazin C; Herrmann E; Zeuzem S
Eur J Gastroenterol Hepatol; 2010 Nov; 22(11):1303-7. PubMed ID: 20729742
[TBL] [Abstract][Full Text] [Related]
11. Serum ferritin levels are associated with a distinct phenotype of chronic hepatitis C poorly responding to pegylated interferon-alpha and ribavirin therapy.
Lange CM; Kutalik Z; Morikawa K; Bibert S; Cerny A; Dollenmaier G; Dufour JF; Gerlach TJ; Heim MH; Malinverni R; Müllhaupt B; Negro F; Moradpour D; Bochud PY;
Hepatology; 2012 Apr; 55(4):1038-47. PubMed ID: 22095909
[TBL] [Abstract][Full Text] [Related]
12. Serum PAI-1 is a novel predictor for response to pegylated interferon-α-2b plus ribavirin therapy in chronic hepatitis C virus infection.
Miki D; Ohishi W; Ochi H; Hayes CN; Abe H; Tsuge M; Imamura M; Kamatani N; Nakamura Y; Chayama K
J Viral Hepat; 2012 Feb; 19(2):e126-33. PubMed ID: 22239510
[TBL] [Abstract][Full Text] [Related]
13. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.
Yu ML; Dai CY; Huang JF; Chiu CF; Yang YH; Hou NJ; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
Hepatology; 2008 Jun; 47(6):1884-93. PubMed ID: 18508296
[TBL] [Abstract][Full Text] [Related]
14. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
Soresi M; Tripi S; Franco V; Giannitrapani L; Alessandri A; Rappa F; Vuturo O; Montalto G
Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
[TBL] [Abstract][Full Text] [Related]
15. Relationship of interferon-γ-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4.
Al-Ashgar HI; Khan MQ; Helmy A; Al-Thawadi S; Al-Ahdal MN; Khalaf N; Al-Qahtani A; Sanai FM
Eur J Gastroenterol Hepatol; 2013 Apr; 25(4):404-10. PubMed ID: 23470264
[TBL] [Abstract][Full Text] [Related]
16. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/HIV co-infected patients.
Crespo M; Esteban JI; Ribera E; Falco V; Sauleda S; Buti M; Esteban R; Guardia J; Ocaña I; Pahissa A
AIDS; 2007 Feb; 21(4):477-81. PubMed ID: 17301566
[TBL] [Abstract][Full Text] [Related]
17. Do steatosis and steatohepatitis impact on sustained virological response (SVR) rates in patients receiving pegylated interferon and ribavirin for chronic hepatitis C infection?
Cross TJ; Quaglia A; Nolan J; Hughes S; Harrison PM
J Med Virol; 2010 May; 82(6):958-64. PubMed ID: 20419809
[TBL] [Abstract][Full Text] [Related]
18. Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
Elefsiniotis IS; Pavlidis C; Ketikoglou I; Koutsounas S; Scarmeas N; Pantazis KD; Moulakakis A; Tsianos EV
Eur J Intern Med; 2008 Jun; 19(4):266-70. PubMed ID: 18471675
[TBL] [Abstract][Full Text] [Related]
19. Adipokines and insulin resistance, predictors of response to therapy in Egyptian patients with chronic hepatitis C virus genotype 4.
Saad Y; Ahmed A; Saleh DA; Doss W
Eur J Gastroenterol Hepatol; 2013 Aug; 25(8):920-5. PubMed ID: 23442415
[TBL] [Abstract][Full Text] [Related]
20. Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.
Cargnel A; Angeli E; Mainini A; Gubertini G; Giorgi R; Schiavini M; Duca P;
Antivir Ther; 2005; 10(2):309-17. PubMed ID: 15865225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]